Bora Youn, M.P.H., M.S.

The treatment approach for advanced non-small cell lung cancer (NSCLC) has been evolving rapidly with the introduction of novel chemotherapies, targeted therapies, and immunotherapies. Despite the rapid expansion of therapeutic options for advanced NSCLC, little is known about the real-world impact of these new treatments, particularly among elderly patients. This study aims to examine the patterns of use, survival, and cost of novel treatments that are commonly used for advanced NSCLC patients receiving care in routine oncology practice. We will investigate a population-based sample of advanced NSCLC Medicare patients in the U.S. Our findings can generate important evidence on the expected clinical and financial impact of common treatment options, enable patients and providers make informed decisions, and advance evidence-based cancer care.